

1. Michelson DJ, Shevell MI, Sherr EH, et al. Evidence report: genetic and metabolic testing in children with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology* 2011;77:1629–1635.
2. Trevathan E. So what? Does the test lead to improved health outcomes? *Neurology* 2011;77:1586–1587.
3. Dravet C. Dravet syndrome history. *Dev Med Child Neurol* 2011;53(suppl 2):1–6.
4. Fiumara A, Pittalà A, Cocuzza M, Sorge G. Epilepsy in patients with Angelman syndrome. *Ital J Pediatr* 2010;36:31.
5. Rauchenzauner M, Klepper J, Leiendecker B, et al. The ketogenic diet in children with Glut1 deficiency syndrome and epilepsy. *J Pediatr* 2008;153:716–718.
6. Rodríguez-Escudero I, Oliver MD, Andrés-Pons A, et al. A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes. *Hum Mol Genet* 2011;20:4132–4142.
7. Coulter ME, Miller DT, Harris DJ, et al. Chromosomal microarray testing influences medical management. *Genet Med* 2011;13:770–776.
8. Saam J, Gudgeon J, Aston E, et al. How physicians use array comparative genomic hybridization results to guide patient management in children with developmental delay. *Genet Med* 2008;10:181–186.
9. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. *Lancet* 2010;376:1417–1427.
10. Joy P, Black C, Rocca A, et al. Neuropsychological functioning in children with medium chain acyl coenzyme a dehydrogenase deficiency (MCADD): the impact of early diagnosis and screening on outcome. *Child Neuropsychol* 2009;15:8–20.
11. Hurler Kölker S, Christensen E, Leonard JV, et al. Diagnosis and management of glutaric aciduria type I: revised recommendations. *J Inher Metab Dis* 2011;34:677–694.
12. Chien YH, Lee NC, Thurberg BL, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. *Pediatrics* 2009;124:e1116–e1125.
13. Muenzer J, Wraith JE, Clarke LA, International Consensus Panel on Management, Treatment of Mucopolysaccharidosis I. Mucopolysaccharidosis I: management and treatment guidelines. *Pediatrics* 2009;123:19–29.
14. National Institutes of Health. Available at: <http://www.clinicaltrials.gov>. Accessed October 31, 2011.
15. The Simons Foundation Autism Research Initiative. Available at: <https://s1.sfari.org/simons-vip>. Accessed October 31, 2011.
16. Sanders SJ, Ercan-Sencicek AG, Hus V, et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. *Neuron* 2011;70:863–885.
17. Grosse SD, Schechter MS, Kulkarni R, et al. Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. *Pediatrics* 2009;123:407–412.
18. Centers for Disease Control and Prevention (CDC). Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment: United States, 2003. *MMWR Morb Mortal Wkly Rep* 2004;53:57–59.
19. Najmabadi H, Hu H, Garshasbi M, et al. Deep sequencing reveals 50 novel genes for recessive cognitive disorders. *Nature* 2011;478:57–63.
20. Vissers LE, de Ligt J, Gilissen C, et al. A de novo paradigm for mental retardation. *Nat Genet* 2010;42:1109–1112.
21. Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. *Am J Hum Genet* 2010;86:749–764.
22. Yeargin-Allsopp M, Boyle C, van Naarden-Braun K, Trevathan E. The epidemiology of developmental disabilities. In: Accardo PJ, ed. *Capute and Accardo's Neurodevelopmental Disabilities in Infancy and Childhood*, 3rd ed. Baltimore: Paul H. Brookes Publishing Co; 2008: 61–104.
23. Senate Subcommittee Markup of FY12 Labor-HHS Appropriations Bill, September 20, 2011. Audio available at: <http://appropriations.senate.gov/webcasts>.

### CORRECTION

#### Statin use and outcome after intracerebral hemorrhage: Case-control study and meta-analysis

In the article “Statin use and outcome after intracerebral hemorrhage: Case-control study and meta-analysis” by W.G. Herrington et al. (*Neurology*® 2011;77:2073–2074), there is an error in the second paragraph. The final sentence should read: “Because the risk of ischemic stroke is higher than risk of ICH in most populations, the net benefit of statins on any stroke is still clear.” The editorial staff regrets the error.

# Neurology<sup>®</sup>

## **Statin use and outcome after intracerebral hemorrhage: Case-control study and meta-analysis**

*Neurology* 2012;78;442  
DOI 10.1212/WNL.0b013e318247f96c

**This information is current as of February 6, 2012**

**Updated Information & Services**

including high resolution figures, can be found at:  
<http://n.neurology.org/content/78/6/442.full>

**Permissions & Licensing**

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:  
[http://www.neurology.org/about/about\\_the\\_journal#permissions](http://www.neurology.org/about/about_the_journal#permissions)

**Reprints**

Information about ordering reprints can be found online:  
<http://n.neurology.org/subscribers/advertise>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2012 by AAN Enterprises, Inc.. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

